Christopher Ballas, PhD
Chris brings over 20 years’ experience working on cell and gene therapies. Most recently he served as Senior Director of Process Development and Commercialization for WuXi Apptec after having had responsibility there for Manufacturing Operations and Program Management for gene therapy clients. Chris was responsible for key programs including CAR-T, TIL, and classic CD34+ stem cell gene therapy.
Previously Chris was responsible for running autologous cell therapy clinical trials for Cook Medical which included several different indications and studies from feasibility through Phase III/pivotal. Prior to Cook, Chris was at the Indiana University School of Medicine in several roles. He developed the initial, scalable, clinical production capabilities for lentiviral vector at the IU Vector Production Facility. He also served as faculty and developed his own research programs on targeting of stem cells for gene therapy which resulted in collaborative development of an ultra-high throughput microinjection device with colleagues at the University of California Riverside (US9885059). Chris has served as an expert consultant to numerous companies on gene therapy and the production and use of viral vectors for gene therapies with contributions to CMC, regulatory filings, and regulatory meetings.
Chris has a Ph.D. in Cellular and Molecular Pathology from Vanderbilt University School of Medicine and was a Children’s Brittle Bone Foundation Fellow during his post-doctoral fellowship at Case Western Reserve University School of Medicine. He has a passion for driving gene therapy forward by solving the practical challenges associated with producing and using viral vectors to treat genetic diseases.Back to Management